Edilio Borroni

Dr. Edilio Borroni

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2018 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
DWDean Wong
Dean Wong
RCRobert A. Comley
Robert A. Comley
HKHiroto Kuwabara
Hiroto Kuwabara
PRPaul B. Rosenberg
Paul B. Rosenberg
SRSusan M. Resnick
Susan M. Resnick
EBEdilio Borroni
Edilio Borroni
11C-RO-963, 11C-RO-643, and 18F-RO-948 (previously referred to as 11C-RO6924963, 11C-RO6931643, and 18F-RO6958948, respectively) have been reported as promising PET tracers for tau imaging based on in vitro and preclinical PET data. Here we describe the first, to our knowledge, human evaluation of these novel radiotracers. Methods: Amyloid PET–positive Alzheimer disease (AD) subjects and younger controls each received 2 different tau tracers. Dynamic 90-min scans were obtained after bolus injection of 11C-RO-963, 11C-RO-643, or 18F-RO-948. Arterial blood sampling was performed on 11 healthy controls and 11 AD subjects. Regions were defined on MR images, and PET data were quantified by plasma reference graphical analysis (for total distribution volume) and target cerebellum ratio (SUV ratios of 60- to 90-min frames). SUV ratio images were also analyzed voxelwise. Five older controls each underwent 2 scans with 18F-RO-948 for evaluation of test–retest variability. Four AD subjects underwent a repeated 18F-RO-948 scan 6–22 mo after the first scan. Six additional healthy controls (3 men and 3 women; age range, 41–67 y) each underwent 1 whole-body dosimetry scan with 18F-RO-948. Results: In younger controls, SUVpeak was observed in the temporal lobe with values of approximately 3.0 for 11C-RO-963, 1.5 for 11C-RO-643, and 3.5 for 18F-RO-948. Over all brain regions and subjects, the trend was for 18F-RO-948 to have the highest SUVpeak, followed by 11C-RO-963 and then 11C-RO-643. Regional analysis of SUV ratio and total distribution volume for 11C-RO-643 and 18F-RO-948 clearly discriminated the AD group from the healthy control groups. Compartmental modeling confirmed that 11C-RO-643 had lower brain entry than either 11C-RO-963 or 18F-RO-948 and that 18F-RO-948 showed better contrast between (predicted) areas of high versus low tau accumulation. Thus, our subsequent analysis focused on 18F-RO-948. Both voxelwise and region-based analysis of 18F-RO-948 binding in healthy controls versus AD subjects revealed multiple areas where AD subjects significantly differed from healthy controls. Of 22 high-binding regions, 13 showed a significant group difference (after ANOVA, F(1,21) = 45, P < 10−5). Voxelwise analysis also revealed a set of symmetric clusters where AD subjects had higher binding than healthy controls (threshold of P < 0.001, cluster size > 50). Conclusion: 18F-RO-948 demonstrates characteristics superior to 11C-RO-643 and 11C-RO-963 for characterization of tau pathology in AD. Regional binding data and kinetic properties of 18F-RO-948 compare favorably with other existing tau PET tracers.

1 September 2017 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
EBEdilio Borroni
Edilio Borroni
BBBernd Bohrmann
Bernd Bohrmann
FGFiona Grueninger
Fiona Grueninger
EPEric Prinssen
Eric Prinssen
SNStephane Nave
Stephane Nave
ACAndrea M Cesura
Andrea M Cesura
Monoamine oxidase B (MAO-B) has been implicated in the pathogenesis of Alzheimer9s disease (AD) and other neurodegenerative disorders. Increased MAO-B expression in astroglia has been observed adjacent to amyloid plaques in AD patient brains. This phenomenon is hypothesised to lead to increased production of hydrogen peroxide and reactive oxygen species (ROS), thereby contributing to AD pathology. Therefore, reduction of ROS-induced oxidative stress via inhibition of MAO-B activity may delay the progression of the disease. In the present study we report the pharmacological properties of sembragiline, a novel selective MAO-B inhibitor specifically developed for the treatment of AD, and on its effect on ROS-mediated neuronal injury and astrogliosis in MAO-B transgenic animals. Sembragiline showed potent and long-lasting MAO-B-selective inhibition and did not inhibit MAO-A at doses where full inhibition of MAO-B was observed. Such selectivity should translate into a favourable clinical safety profile. Indeed, sembragiline neither induced the serotonin syndrome when administered together with the serotonin precursor L-5-hydroxytryptophan in combination with antidepressants such as fluoxetine, nor potentiated the pressor effect of tyramine. Additionally, in experiments using a transgenic animal model conditionally overexpressing MAO-B in astroglia, sembragiline protected against neuronal loss and reduced both ROS formation and reactive astrogliosis. Taken together, these findings warrant further investigation of the potential therapeutic benefit of MAO-B inhibitors in patients with AD and other neurological disorders.

10 August 2018 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
HKHiroto Kuwabara
Hiroto Kuwabara
RCRobert A. Comley
Robert A. Comley
EBEdilio Borroni
Edilio Borroni
MHMichael Honer
Michael Honer
KKKelly Kitzmiller
Kelly Kitzmiller
DWDean F. Wong
Dean F. Wong
Rationale: The availability of tau PET radioligands enables quantitative assessment of tau density and distribution in the human brain. We evaluated the kinetics of a novel radioligand 18F-RO-948 (previously referred to as 18F-RO6958948) and its ability to identify tau-positivity in individual patients with mild Alzheimer’s disease (AD). Methods: Eleven amyloid-positive, mild AD subjects, five amyloid-negative older (OC), and five younger (YC) control subjects completed one or two (4 AD and 5 OC) PET scans with 18F-RO-948 for 90, 120, or 200 min. The kinetics of the radioligand was evaluated with standard compartmental and non-compartmental models (with plasma data in 70% of cases), tissue-reference methods, and the standardized uptake value ratio (SUVR). These approaches were applied to assess the ability of 18F-RO-948 to discriminate AD subjects from OC subjects. Results: The plasma reference graphical analysis (PRGA) appeared to be the optimal method of quantification for 18F-RO-948, yielding strictly time-consistent values of distribution volume (VT) and distribution volume ratio (DVR) at 90 min against the 120 and 200 min analyses. The reference tissue graphical analysis (RTGA) and SUVR were cross-validated against PRGA. Test-retest showed excellent reproducibility. A proposed novel index of tau load, the Tau-Positive Fractions of regions (TPF) showed high values in medial and lateral temporal and parietal regions in AD, and successfully separated AD from OC and YC with a significant margin. Conclusion: 18F-RO-948 appears to be a promising radioligand for quantitative imaging of tau in the brain of Alzheimer’s disease patients.

1 June 2023 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
ALAntoine Leuzy
Antoine Leuzy
ABAlexa Pichet Binette
Alexa Pichet Binette
JVJacob W. Vogel
Jacob W. Vogel
GKGregory Klein
Gregory Klein
EBEdilio Borroni
Edilio Borroni
JHJohn Hsiao
John Hsiao
Importance: Longitudinal tau positron emission tomography (PET) is a relevant outcome in clinical trials evaluating disease-modifying therapies in Alzheimer disease (AD). A key unanswered question is whether the use of participant-specific (individualized) regions of interest (ROIs) is superior to conventional approaches where the same ROI (group-level) is used for each participant.Objective: To compare group- and participant-level ROIs in participants at different stages of the AD clinical continuum in terms of annual percentage change in tau-PET standardized uptake value ratio (SUVR) and sample size requirements.Design, Setting, and Participants: This was a longitudinal cohort study with consecutive participant enrollment between September 18, 2017, and November 15, 2021. Included in the analysis were participants with mild cognitive impairment and AD dementia from the prospective and longitudinal Swedish Biomarkers For Identifying Neurodegenerative Disorders Early and Reliably 2 (BioFINDER-2) study; in addition, a validation sample (the AVID 05e, Expedition-3, Alzheimer’s Disease Neuroimaging Initiative [ADNI], and BioFINDER-1 study cohorts) was also included.Exposures: Tau PET (BioFINDER-2, [18F]RO948; validation sample, [18F]flortaucipir), 7 group-level (5 data-driven stages, meta-temporal, whole brain), and 5 individualized ROIs.Main Outcomes and Measures: Annual percentage change in tau-PET SUVR across ROIs. Sample size requirements in simulated clinical trials using tau PET as an outcome were also calculated.Results: A total of 215 participants (mean [SD] age, 71.4 (7.5) years; 111 male [51.6%]) from the BioFINDER-2 study were included in this analysis: 97 amyloid-β (Aβ)–positive cognitively unimpaired (CU) individuals, 77 with Aβ-positive mild cognitive impairment (MCI), and 41 with AD dementia. In the validation sample were 137 Aβ-positive CU participants, 144 with Aβ-positive MCI, and 125 with AD dementia. Mean (SD) follow-up time was 1.8 (0.3) years. Using group-level ROIs, the largest annual percentage increase in tau-PET SUVR in Aβ-positive CU individuals was seen in a composite ROI combining the entorhinal cortex, hippocampus, and amygdala (4.29%; 95% CI, 3.42%-5.16%). In individuals with Aβ-positive MCI, the greatest change was seen in the temporal cortical regions (5.82%; 95% CI, 4.67%-6.97%), whereas in those with AD dementia, the greatest change was seen in the parietal regions (5.22%; 95% CI, 3.95%-6.49%). Significantly higher estimates of annual percentage change were found using several of the participant-specific ROIs. Importantly, the simplest participant-specific approach, where change in tau PET was calculated in an ROI that best matched the participant’s data-driven disease stage, performed best in all 3 subgroups. For the power analysis, sample size reductions for the participant-specific ROIs ranged from 15.94% (95% CI, 8.14%-23.74%) to 72.10% (95% CI, 67.10%-77.20%) compared with the best-performing group-level ROIs. Findings were replicated using [18F]flortaucipir.Conclusions and Relevance: Finding suggest that certain individualized ROIs carry an advantage over group-level ROIs for assessing longitudinal tau changes and increase the power to detect treatment effects in AD clinical trials using longitudinal tau PET as an outcome.

1 March 2006 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
RPRalph Paulini
Ralph Paulini
CTChristian Trindler
Christian Trindler
CLChristian Lerner
Christian Lerner
LBLukas Brändli
Lukas Brändli
WSW. Bernd Schweizer
W. Bernd Schweizer
FDFrançois Diederich
François Diederich

1 November 2015 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
FAFrauke Assmus
Frauke Assmus
ASAnna Seelig
Anna Seelig
LGLuca Gobbi
Luca Gobbi
EBEdilio Borroni
Edilio Borroni
PGPatricia Glaentzlin
Patricia Glaentzlin
HFHolger Fischer
Holger Fischer